To drive change, medicine requires hard data to supply evidence of clinical benefit. However, the studies we rely on to make decisions about a drug’s efficacy are often statistically underpowered – that is, therapeutic trials may fail to show the benefit of agents or devices when a benefit does, in fact, exist. This is due to limited data from smallpatient populations or too much variability in the data.
We performed analyses of studies of anticoagulation in electrical cardioversion to examine this problem more clearly. We also show how proactive data pooling could help to mitigate limitations in statistical power. Continue reading